DNA Repair data presented at American Academy of Dermatology Meeting
First results of afamelanotide in xeroderma pigmentosum C (XPC) presented to Photodermatology...
Read More
PRÉNUMBRA® Formulation Completed For Clinical Trial Use
CLINUVEL today announced the completion of manufacture of the first cGMP batch...
Read More
Afamelanotide Significantly Reduces UV Skin Damage in a Healthy Population - Technical Note
Melbourne, Australia, 02 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals
Results released today from a clinical study have shown that the drug...
Read More
Afamelanotide Significantly Reduces UV Skin Damage in a Healthy Population
Melbourne, Australia, 02 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Media release: CLINUVEL Trial Results Show Drug Reduces DNA Damage
Results from a clinical trial in a genetic DNA repair disorder show...
Read More
Afamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum - Technical Note
Melbourne, Australia, 16 January 2023 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Afamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum
First Phase II results show decrease in UV-induced skin damage
Read More
First vitiligo patient enrolled in afamelanotide monotherapy study
CUV104 study to evaluate the role of afamelanotide as monotherapy in patients...
Read More
CLINUVEL submits SCENESSE® label expansion for adolescent EPP patients
European regulatory submission follows clinical support for SCENESSE® treatment in EPP patients...
Read More
PRÉNUMBRA® for stroke
Melbourne, Australia, 28 July 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
CLINUVEL progresses vitiligo treatment program
A new potential therapy for the pigment loss disorder vitiligo will undergo...
Read More
Positive final results in stroke
CLINUVEL today released positive final results of the open label pilot study...
Read More
CLINUVEL Extends Employment Agreement With CEO
CLINUVEL today announced that it has extended the Employment Agreement with the...
Read More
DNA Repair Communiqué II
In this DNA Repair Communiqué II we delve deeper into the topic...
Read More